Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q4 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $193.5 thousand.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.